In its latest quarterly filing, Greenwich LifeSciences confirmed progress in its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy targeting HER2-positive breast cancer. FDA clearance allowing commercial-scale GP2 peptide supply enhances operational scalability as the company expands trial sites up to 150 globally. Early clinical data indicate meaningful reductions in cancer recurrence, reinforcing the potential of the GP2+GM-CSF regimen. Despite solid liquidity positioning with a current ratio above 2.0, GLSI remains reliant on continued financing amid sustained net losses typical of clinical-stage biotech firms.